New concepts in antimicrobial susceptibility testing: The mutant prevention concentration and mutant selection window approach

Veterinary Dermatology

Volumn 20, Issue 5-6, 2009, Pages 383-396

  Blondeau, Joseph M ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; DOSE RESPONSE; DRUG EFFECT; GENETIC SELECTION; GENETICS; MICROBIOLOGICAL EXAMINATION; MUTATION;

ANTI-BACTERIAL AGENTS; BACTERIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; SELECTION, GENETIC;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 73149107738     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2009.00856.x     Document Type: Article

References (48)

1. Blondeau JM. Extended spectrum beta-lactamases (ESBL). Seminars in Respiratory Infections 2001 16 : 169 176.
2. Johnson CC. In vitro testing: correlations of bacterial susceptibility, body fluid levels and effectiveness of antibacterial therapy. In : Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Maryland, Williams & Wilkins, 1996 : 813 834.
3. Blondeau JM, Hansen G, Metzler KL et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. Journal of Chemotherapy 2004 16 : 1 19.
4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard - 7th edn. Wayne, PA M7-A7), Volume 26, 2006.
5. Dong Y, Zhao X, Domagala J et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 1999 43 : 1756 1758.
6. Blondeau J, Zhao X, Hansen GT et al. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 2001 45 : 433 438.
7. Hesje C, Blondeau J. Comparison of modified microbroth dilution to agar dilution for determining the mutant prevention concentration of gatifloxacin and moxifloxacin against Staphylococcus aureus strains. In : 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC : 2008 : Abstract #D-2245.
8. Firsch AW, Tripp JT, Barrett CD Jr. et al. Specific polysaccaride content of pneumoni lungs. Journal of Experimental Medicine 1942 76 : 505 510.
9. Feldman W. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. Journal of Pediatrics 1976 88 : 549 552.
10. Fagon J, Chastre J, Trouillet JL et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. American Review of Respiratory Disease 1990 142 : 1004 1008.
11. Bingen E, Lambert-Zechovsky N, Mariani-Kurkdjian P et al. Bacterial counts in cerebrospinal fluid of children with meningitis. European Journal of Clinical Microbiology and Infectious Diseases 1990 9 : 278 281.
12. Davidson RJ, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 2002 346 : 747 750.
13. Anderson KB, Tan JS, File TM Jr. et al. Emergence of levofloxacin- resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clinical Infectious Diseases 2003 37 : 376 381.
14. Blondeau JM, Borsos S, Hesje C et al. Comparative killing of bovine isolates of Mannheimia haemolytica (MH) by enrofloxacin (ENR), florfenicol (FL), tilmicosin (TIL) and tulathromcyin (TUL) using the measured minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) drug values. In : Vienna, Austria, International Meeting on Emerging Diseases and Surveillance (IMED) : 2007 : Abstract #04898.
15. Blondeau JM, Borsos S, Blondeau LD et al. Concentration dependent killing of Mannheimia haemolytica (MH) by enrofloxacin at the minimum inhibitory, mutant prevention, maximum serum and tissue drug concentrations. In : International Meeting of Emerging Diseases and Surveillance (IMED), Vienna, Austria : 2007 : Abstract #04904.
16. Hansen G, Metzler KL, Drlica K et al. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 2003 47 : 440 441.
17. Blondeau JM, Hansen G, Metzler KL et al. Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin. In : Gillespie SH, Tillotson GS, eds. Novel Perspectives in Antibacterial Action. London, Royal Society of Medicine Press Limited, 2002 : 15 26.
18. Blondeau JM, Blondeau LD, Hesje C et al. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones. Journal of Chemotherapy 2006 18 : 366 372.
19. Blondeau JM, Borsos S. Application of the resistance prevention concentration (RPC) and minimal inhibitory concentration (MIC) of clinical isolates of Streptococcus pneumoniae (SP) against macrolides. In : World Conference on Dosing of Anti-Infectives: 'Dosing the magic bullets'. Nurnberg, Germany : 2004 : Abstract #70.
20. Smith H, Nichol KA, Hoban DJ et al. Stretching the mutant prevention concentration (MPC) beyond its limits. Journal of Antimicrobial Chemotherapy 2003 51 : 1323 1325.
21. Benet LZ, Sheiner LB. General Principles (Introduction). In : Gillman AG, Goodman L, Rall TW et al. eds. The Pharmacological Basis of Therapeutics, 7th edn. New York, MacMillan Publishing Company, 1985 : 1 2.
22. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clinical Infectious Diseases 2001 32 : S39 46.
23. Drusano GL, Preston SL, Owens RC Jr. et al. Fluoroquinolone pharmacodynamics (Correspondence). Clinical Infectious Diseases 2001 33 : 2091 2092.
24. Schentag JJ, Gilliland KK, Paladino JA. Fluoroquinolone pharmacodynamics (reply). Clinical Infectious Diseases 2001 33 : 2092 2096.
25. Lees P, Concordet D, Aliabadi FS et al. Drug selection and optimization of dosage schedules to minimize antimicrobial resistance (Chapter 5). In : Aarestrap FM, ed. Antimicrobial Resistance in Bacteria of Animal Origin. Washington, ASM Press, 2006 : 49 71.
26. Hesje C, Tillotson GS, Blondeau JM. MICs, MPCs and PK/PDs: a match (sometimes) made in hosts. Expert Review of Respiratory Medicine 2007 1 : 7 16.
27. Zinner SH, Lubenko IY, Gilbert DN et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. Journal of Antimicrobial Chemotherapy 2003 52 : 616 622.
28. Metzler KL, Hansen G, Hedlin P et al. Comparison of minimal inhibitory and mutant prevention concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 2004 24 : 161 167.
29. Blondeau JM, Borsos S, Hesje C et al. Comparative minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) values of enrofloxacin, florfenicol, tilmicosin and tulathromycin against Mannheimia haemolytica (MH) isolates collected fromf cattle and bovine respiratory disease. In : International Meeting of Emerging Diseases and Surveillance (IMED), Vienna, Austria : 2007 : Abstract #04897.
30. Olofsson SK, Marcusson LL, Komp Lindgren P et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. Journal of Antimicrobial Chemotherapy 2006 57 : 1116 1121.
31. Ehrlich P. Chemotherapeutics: scientific principles, methods and results. The Lancet 1913 182 : 445 451.
32. Hedlin P, Blondeau JM. Comparative minimal inhibitory and mutant prevention concentration (MPC) of gatifloxacin (GA) and other compounds against gram-positive ocular pathogens. In : The Association for Research in Vision and Ophthalmology (ARVO) : Fort Lauderdale, Florida : 2004 : Abstract #4920.
33. Blondeau JM, Hesje C, Blondeau LD et al. Determination of the mutant prevention concentration (MPC) for clinical isolates of Streptococcus pneumoniae (SP) with minimum inhibitory concentration (MIC) to azithromycin (AZ), clarithromycin (CL) and erythromycin (ER) of ≤0.125 mg/L. In : 12th International Congress on Infectious Diseases (ICID) : Lisbon, Portugal : 2006 : Abstract #29.053.
34. Blondeau JM, Tillotson GS. Comparative minimum inhibitory (MI) and mutant prevention (MP) drug concentrations (C) of gatifloxacin (Gat), gemifloxacin (Gem) and moxifloxacin (Mfx) against clinical isolates of Streptococcus pneumoniae (SP) with MICs to levofloxacin (Lfx) of ≥2 mg/L. In : 12th International Congress on Infectious Diseases (ICID), Lisbon, Portugal : 2006 : Abstract #56.030.
35. Metzler KL, Borsos S, Blondeau JM. Application of the mutant prevention concentration (MPC) for Streptococcus pneumoniae (SP) against azithromycin (AZ), clarithromycin (CL) and erythromycin (ER). In : 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic : 2004 : Abstract #P1744.
36. Blondeau JM, Borsos S, Hedlin P et al. Determination of the minimum inhibitory concentration and mutant prevention concentration of garenoxacin against over 500 clinical isolates of Streptococcus pneumoniae. In : 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, 2005 : Abstract #P1211.
37. Blondeau JM, Drlica K, Hansen G et al. The mutant prevention concentration (MPC) of gemifloxacin against clinical isolates of Streptococcus pneumoniae (SP) that are susceptible (PS), intermediate (PI) or resistant (PR) to penicillin. In : 7th International Symposium on New Quinolones, Edinburgh, Scotland : 2001 : Abstract #P81.
38. Allen GP, Kaatz GW, Rybak MJ. In vitro activities oif mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. International Journal of Antimicrobial Agents 2004 24 : 150 160.
39. Blondeau JM, Metzler KL. Application of the resistance prevention concentration (RPC) to oxacillin (O), cefazolin (C) and vancomycin (C) against methicillin-susceptible (MS) and resistant (MR) Staphylococcus aureus (SA). In : 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, American Society of Microbiology, Washington, DC : 2005 : Abstract #C2-297.
40. Wetzstein HG. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrobial Agents and Chemotherapy 2005 49 : 4166 4173.
41. Hansen G, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric gram-negative urinary tract infection pathogens. Journal of Chemotherapy 2005 17 : 484 492.
42. Blondeau JM, Borsos S, Hesje C. Determination of the minimum inhibitory and mutant prevention concentrations of moxifloxacin against clinical isolates of E. coli and Klebsiella species. In : 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Munich, Germany : March 31-April 3, 2007 : Abstract #P-1654.
43. Metzler KL, Hedlin P, Blondeau JM. Determination of minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC) of ocular isolates of Pseudomonas aeruginosa and Haemophilus influenzae to 5 fluoroquinolone antimicrobial agents. In : Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL : 2004 : Abstract #4988.
44. Blondeau JM, Borsos S. Comparative minimum inhibitory concentration and mutant preveniton concentration of azithromycin, cefuroxime, gemifloxacin, moxifloxacin and telithromycin against clinical isolates of Haemophilus influenzae., In : 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Munich, Germany : 2007 : Abstract #P-747.
45. Hedlin P, Blondeau JM. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae. Eye & Contact Lens 2007 33 : 161 164.
46. Blondeau JM, Borsos S, Hesje C. Determination of the minimum inhibitory and mutant prevention concentration of tigecycline against clinical isolates of E. coli and Klebsiella species. In : 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Munich, Germany : 2007 : Abstract #P-1653.
47. Hansen G, Zhao X, Drlica K et al. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aerugi nosa. International Journal of Antimicrobial Agents 2006 27 : 120 124.
48. Randall LP, Cooles SW, Piddock LJV et al. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonells enterica. Journal of Antimicrobial Chemotherapy 2004 54 : 688 691.